Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing ...
We read with interest the Rome Foundation paediatric global study by Nurko and colleagues,1 which establishes a multinational ...
Background The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after ...
Background Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in ...
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers, portending poor patient outcomes ...
Background Hospitalisations represent major clinical events in cirrhosis, yet prediction based on clinical variables alone ...
Background Pain in chronic pancreatitis (CP) is multifactorial. Efficacy of pancreatic enzyme replacement therapy (PERT) for pain remains uncertain. Objective To assess the effect of ...
The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy ...
Recent work in Gut has highlighted multi-kingdom interactions between gut bacteria and bacteriophage (‘phage’) as contributors to Crohn’s disease.1 Whether similar alterations characterise colorectal ...
Background Patients with gastric cancer (GC) and peritoneal metastasis (PM) have poor prognoses due to drug resistance and metastatic relapse. The mechanism underlying PM recurrence remains unclear.
Background New-onset diabetes (NOD) increases the risk of pancreatic cancer. Previous studies have mainly focused on the presence or absence of diabetes, with limited attention to NOD severity at ...
We would like to thank von Muhlenbrock et al for their letter1 and for their interest in our recent network meta-analysis.2 Some gut-brain neuromodulators, particularly tricyclic antidepressants (TCAs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results